Vaccine PREVENAR 13 – (9000) at Dr. Essa Lab

Vaccine PREVENAR 13 – (9000) at Dr. Essa Lab

Vaccine PREVENAR 13 – (9000) is a sterile, ready-to-use suspension of saccharides from the capsular antigens of 13 serotypes of Streptococcus pneumoniae. Each serotype is individually conjugated to a non-toxic diphtheria carrier protein known as CRM197. Streptococcus pneumoniae, commonly referred to as pneumococcus, is a highly virulent Gram-positive bacterium responsible for a substantial global burden of morbidity and mortality. It is the primary causative pathogen in invasive pneumococcal diseases (IPD) such as meningitis, bacteremia, and septicemia, as well as non-invasive mucosal infections including community-acquired pneumonia (CAP) and acute otitis media. Dr. Essa Laboratory & Diagnostic Centre, a premier diagnostic institution in Karachi, Pakistan, offers this vital immunization to safeguard pediatric, adult, and geriatric populations against these life-threatening bacterial infections.

The conjugate technology utilized in Vaccine PREVENAR 13 – (9000) represents a monumental advancement in vaccinology. Traditional polysaccharide vaccines often fail to elicit a robust immune response in infants and young children because their immune systems are immunologically immature and cannot process T-cell-independent antigens effectively. By chemically conjugating the pneumococcal capsular polysaccharides to the CRM197 carrier protein, the vaccine converts the immunological response from a T-cell-independent to a T-cell-dependent pathway. This shift induces a strong primary antibody response, stimulates high-affinity IgG production, and establishes long-term immunological memory. Consequently, this vaccine provides robust, durable protection starting in early infancy, which is the period of highest vulnerability.

The clinical importance of Vaccine PREVENAR 13 – (9000) cannot be overstated. Pneumococcal infections can progress rapidly, causing severe tissue damage, neurological sequelae in the case of meningitis, and systemic inflammatory response syndrome (SIRS) in bacteremic patients. Immunization serves as the primary defense mechanism, significantly reducing the carriage rates of vaccine-type pneumococci in the nasopharynx. This reduction not only protects the vaccinated individual but also fosters herd immunity within the community, protecting unvaccinated infants and vulnerable older adults. At Dr. Essa Lab, the administration of this vaccine is conducted under strict clinical protocols, ensuring that patients receive potent, properly stored vaccines administered by highly trained healthcare professionals.

Clinical Procedure: What to Expect

Patient Preparation

• Medical History Review: Inform the healthcare provider at Dr. Essa Lab of any known allergies, especially to previous doses of pneumococcal vaccines or any vaccine containing diphtheria toxoid.
• Acute Illness Assessment: If the patient is experiencing a moderate to severe acute illness accompanied by a high fever, it is advisable to defer vaccination until the illness has resolved. Mild infections, such as a common cold or low-grade fever, are generally not contraindications.
• Bleeding Disorders: Inform the clinical staff if the patient has a bleeding disorder, such as hemophilia, or is taking anticoagulant therapy, as special precautions must be taken during intramuscular administration to prevent hematoma formation.
• Immunosuppressive Therapy: Disclose if the patient is undergoing chemotherapy, radiation therapy, or taking high-dose corticosteroids, as these treatments may reduce the immune response to the vaccine.
• No Fasting Required: There are no dietary restrictions or fasting requirements prior to receiving Vaccine PREVENAR 13 – (9000). Patients can eat and drink normally.
• Vaccination Records: Bring all previous immunization records to Dr. Essa Lab to ensure proper scheduling and documentation.

During the Procedure

The administration of Vaccine PREVENAR 13 – (9000) at Dr. Essa Lab follows a standardized clinical protocol to ensure patient safety and comfort. Upon arrival, the clinical staff will verify the patient’s identity, review the medical history, and inspect the vaccine vial to ensure proper cold-chain maintenance and expiration dates. The vaccine is a homogeneous, white, turbid suspension; the clinician will shake the pre-filled syringe vigorously before administration to ensure uniform suspension.

The patient is positioned comfortably. For infants and toddlers, the preferred site of administration is the anterolateral aspect of the thigh (vastus lateralis muscle). For older children and adults, the vaccine is administered into the deltoid muscle of the upper arm. The clinician cleanses the injection site with an alcohol swab and allows it to air dry. The vaccine is administered via a deep intramuscular injection at a 90-degree angle to the skin surface. After injecting the 0.5 mL dose, the needle is withdrawn, and gentle pressure is applied to the site with a sterile cotton ball. The patient is advised to remain in the waiting area for 15 to 30 minutes post-injection to monitor for any immediate hypersensitivity or anaphylactic reactions, which, although extremely rare, can be managed promptly by the on-site medical team.

When is a Vaccine PREVENAR 13 – (9000) Performed?

Routine Pediatric Immunization Schedules

Vaccine PREVENAR 13 – (9000) is routinely administered to infants starting as early as 6 weeks of age. The standard pediatric schedule consists of a primary series of three doses given at 2, 4, and 6 months of age, followed by a booster dose at 12 to 15 months. This routine schedule is critical because infants have an immature immune system and are highly susceptible to invasive pneumococcal diseases. Early immunization ensures that protective antibody levels are established before the child reaches the peak age of vulnerability for pneumococcal infections.

Adults Aged 65 Years and Older

As individuals age, they undergo immunosenescence, a progressive decline in immune function that increases susceptibility to infectious diseases. Pneumococcal pneumonia is a leading cause of hospitalization and death among older adults. Clinical guidelines recommend Vaccine PREVENAR 13 – (9000) for adults aged 65 and older to boost their immune defenses against the 13 serotypes covered by the vaccine, significantly reducing the risk of community-acquired pneumonia and invasive pneumococcal bacteremia.

Immunocompromised Individuals

Physicians frequently prescribe Vaccine PREVENAR 13 – (9000) for individuals with compromised immune systems. This includes patients with congenital or acquired immunodeficiencies, HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin’s disease, or generalized malignancy. It is also highly recommended for patients receiving immunosuppressive treatments, such as chemotherapy or organ transplant regimens. These individuals are at an extraordinarily high risk of developing severe, disseminated pneumococcal infections.

Patients with Chronic Medical Conditions

Chronic underlying illnesses significantly impair the body’s ability to clear bacterial pathogens from the respiratory tract. Vaccine PREVENAR 13 – (9000) is indicated for individuals aged 2 through 64 years with chronic cardiovascular disease (congestive heart failure, cardiomyopathies), chronic pulmonary disease (including chronic obstructive pulmonary disease, emphysema, and severe asthma), diabetes mellitus, or chronic liver disease (including cirrhosis). Immunization helps prevent acute exacerbations of these underlying conditions triggered by pneumococcal infections.

Individuals with Anatomical Risk Factors

Certain anatomical conditions create a direct pathway for bacteria to enter the central nervous system or blood stream. Patients with cerebrospinal fluid (CSF) leaks, cochlear implants, or anatomical or functional asplenia (such as sickle cell disease or post-splenectomy status) are at an elevated risk for pneumococcal meningitis and overwhelming post-splenectomy infection (OPSI). For these patients, receiving Vaccine PREVENAR 13 – (9000) is a critical preventive measure to avert catastrophic neurological and systemic complications.

What Does Vaccine PREVENAR 13 – (9000) Prevent and Protect Against?

Vaccine PREVENAR 13 – (9000) is designed to stimulate active immunization for the prevention of invasive disease, pneumonia, and otitis media caused by Streptococcus pneumoniae. The vaccine specifically targets and protects against the following clinical entities, bacterial serotypes, and associated complications:

• Streptococcus pneumoniae Serotype 1: A major cause of invasive disease and empyema in children and young adults.
• Streptococcus pneumoniae Serotype 3: Associated with severe, necrotizing pneumonia and high mortality rates in older adults.
• Streptococcus pneumoniae Serotype 4: Frequently isolated from patients with bacteremic pneumococcal pneumonia.
• Streptococcus pneumoniae Serotype 5: Commonly linked to outbreaks of invasive pneumococcal disease in developing regions.
• Streptococcus pneumoniae Serotype 6A: A serotype historically associated with antibiotic resistance and pediatric otitis media.
• Streptococcus pneumoniae Serotype 6B: Highly prevalent in pediatric populations and a frequent cause of meningitis.
• Streptococcus pneumoniae Serotype 7F: Known for causing severe invasive infections but typically associated with lower mortality than serotype 3.
• Streptococcus pneumoniae Serotype 9V: Often exhibits multi-drug resistance, making vaccine-mediated prevention crucial.
• Streptococcus pneumoniae Serotype 14: The most common serotype causing invasive pneumococcal disease in young children worldwide.
• Streptococcus pneumoniae Serotype 18C: Frequently associated with bacteremia and localized middle ear infections in infants.
• Streptococcus pneumoniae Serotype 19A: A highly aggressive, multi-drug resistant serotype that emerged globally post-PCV7 introduction.
• Streptococcus pneumoniae Serotype 19F: Associated with persistent middle ear infections and antibiotic-resistant strains.
• Streptococcus pneumoniae Serotype 23F: A major contributor to pneumococcal meningitis and bacteremia in pediatric cohorts.
• Pneumococcal Meningitis: A life-threatening infection of the membranes covering the brain and spinal cord, which can lead to permanent hearing loss, cognitive impairment, or death.
• Pneumococcal Bacteremia: The presence of pneumococcal bacteria in the bloodstream, which can rapidly progress to septic shock and multi-organ failure.
• Bacteremic Pneumonia: A severe form of pneumonia where the infection spills over into the bloodstream, significantly worsening the clinical prognosis.
• Community-Acquired Pneumonia (CAP): Infection of the lung parenchyma, leading to alveolar consolidation, severe respiratory distress, and hypoxia.
• Acute Otitis Media (AOM): Painful middle ear infections in infants and young children, which can lead to tympanic membrane perforation and chronic hearing issues.
• Pneumococcal Empyema: A severe complication of pneumonia characterized by the accumulation of pus in the pleural cavity, requiring surgical drainage.
• Pneumococcal Peritonitis: Infection of the peritoneal cavity, particularly in patients with ascites or nephrotic syndrome.
• Pneumococcal Sinusitis: Acute or chronic inflammation of the paranasal sinuses caused by vaccine-preventable pneumococcal strains.
• Secondary Bacterial Infections: Preventing pneumococcal superinfections that often follow primary viral respiratory infections like influenza.
• Overwhelming Post-Splenectomy Infection (OPSI): Rapidly progressive, fatal septicemia in patients lacking a functioning spleen.
• Chronic Bronchitis Exacerbations: Preventing acute bacterial flare-ups in patients suffering from chronic obstructive pulmonary disease (COPD).
• Pneumococcal Arthritis: Septic arthritis of the joints resulting from hematogenous spread of pneumococcal bacteria.

Turnaround Time and Vaccination Records at Dr. Essa Lab

At Dr. Essa Laboratory & Diagnostic Centre, the administration of Vaccine PREVENAR 13 – (9000) is documented immediately. Upon receiving the vaccine, the patient is provided with an official, physical immunization card. This card details the vaccine name, brand, batch or lot number, date of administration, and the signature of the vaccinating clinician. This physical record is essential for pediatric school admissions, international travel requirements, and future medical consultations.

In addition to the physical card, Dr. Essa Lab utilizes an advanced electronic medical records (EMR) system. The vaccination details are uploaded to the patient’s digital portal within minutes of administration. Patients and authorized family members can access these records securely through the Dr. Essa Lab mobile application or official website. This digital archiving ensures that your immunization history is never lost and remains accessible from anywhere in the world, reflecting Dr. Essa Lab’s commitment to modern, patient-centric healthcare delivery.

Vaccine PREVENAR 13 – (9000) Immunization Overview

Parameter / Target Evaluated	Expected Immune Response	Clinical Considerations & Action
Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F	Robust IgG antibody response and immunological memory.	Provides long-term active immunity; essential for pediatric and high-risk adult cohorts.
Injection Site Reaction	Mild localized erythema, swelling, or tenderness.	Normal inflammatory response; typically resolves spontaneously within 24 to 48 hours.
Systemic Response (Fever)	No fever or mild low-grade fever (< 38°C or 100.4°F).	Indicates active immune stimulation; high fevers should be clinically evaluated.
Pediatric Schedule Compliance	Completion of the 4-dose series (2, 4, 6, and 12-15 months).	Crucial for achieving maximum protective efficacy in early childhood.
Adult Immunization Status	Single dose administration for eligible individuals.	Provides sustained protection; may be sequenced with PPSV23 based on medical advice.
Immunocompromised Response	Variable antibody titers depending on the degree of immunosuppression.	Vaccination is still highly recommended; timing relative to therapy should be optimized.
Hypersensitivity Screening	No immediate or delayed allergic reactions.	Contraindicated in individuals with a history of severe anaphylaxis to diphtheria toxoid.
Co-administration with Influenza Vaccine	Synergistic protection against winter respiratory pathogens.	Can be administered concurrently at separate anatomical injection sites.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine PREVENAR 13 – (9000)?

• Experienced Healthcare Professionals: Our clinical staff consists of highly trained, certified vaccinators who adhere to strict aseptic techniques and international injection safety standards.
• Strict Cold Chain Maintenance: Dr. Essa Lab utilizes state-of-the-art refrigeration and continuous temperature monitoring systems to ensure that vaccines are stored at the precise manufacturer-recommended temperatures, preserving maximum potency.
• ISO 15189 Certified Network: As an ISO-certified diagnostic facility, Dr. Essa Lab maintains the highest standards of quality control, safety, and clinical excellence across all branches.
• Convenient Home Vaccination Services: To accommodate infants, elderly patients, and those with mobility challenges, Dr. Essa Lab offers professional home vaccination services throughout Karachi.
• Comprehensive Digital Records: Patients receive immediate digital access to their immunization records via our secure online portal and mobile application, ensuring seamless record-keeping.
• Patient-Focused Care: We prioritize patient comfort, providing a clean, welcoming, and stress-free environment, particularly designed to ease anxiety in pediatric patients.
• Established Trust Since 1987: Founded by Prof. Dr. Farhan Essa Abdullah, Dr. Essa Lab is a household name in Pakistan, built on decades of diagnostic accuracy, clinical integrity, and community trust.
• Commitment to Public Health: We actively participate in preventive medicine initiatives, offering affordable, accessible, and genuine vaccines to protect the community from preventable infectious diseases.